Reading time: 4 minutes Sydney Scatigno Over the last couple of decades, cancer research has made strides in improving the pre-clinical assessment of novel compounds. Compound screening, the process of assessing new compounds for efficacy, across various cell lines is an important step in finding the optimal drug candidate downstream in the drug development process.... Continue Reading →
A Standing Ovation! Results From DESTINY-Breast04 trial in Breast Cancer
Reading time: 5 minutes Patty Spears The applause was thunderous and traveled like a wave across the large auditorium at the end of a 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Session talk. It did not stop. The audience stood and kept applauding and reveling in the positive results of a clinical... Continue Reading →
The Double-Edged Sword of Collagen
Reading time: 4 minutes Sara Musetti If you’ve heard of collagen, it’s likely been in articles raving about its benefits. Maybe it was in the recent collagen broth craze, when everyone from Halle Berry to Dr. Oz claimed that the collagen in bone broth could prevent aging, improve your hair, cure arthritis, and so on.... Continue Reading →
PROTACs: Building better therapies
Reading time: 5 minutes Tamara Vital How do you stop an accident from happening? You could try to prevent the conditions that contribute to accidents by establishing rules that encourage and reward caution and safe behavior. On the road, licensing laws, traffic lights, and speed limits set the rules of the road, and those who... Continue Reading →
Understanding the heterogeneity of triple-negative breast cancer to develop targeted therapies
Reading time: 3 minutes Aishwarya Subramanian Breast cancer has shown to be a really aggressive condition. About 12% of the women in the US are known to develop invasive breast cancer, where the disease spreads into surrounding healthy tissues [a]. Now it is well established that breast cancer is a very heterogeneous disease. Genome studies... Continue Reading →